SCHEMBL574460

SCHEMBL574460

O=P(O)(O)Oc1c(Cl)c(Cl)c(Cl)c(Cl)c1Cl

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
INPPL1 O15357 11/20 0.48
INPP5A Q14642 6/20 0.48
AKT1 P31749 1/20 0.48
INPP5B P32019 2/20 0.44
SRC P12931 5/20 0.38
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA9 Q16790 1/20 0.33
FDPS P14324 1/20 0.33
BLM P54132 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
KDM4E B2RXH2 1/20 0.30
USP2 O75604 1/20 0.30
ALDH1A1 P00352 1/20 0.30
HPGD P15428 1/20 0.30
PDE3A Q14432 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10751352 0.97 INPPL1 (0.46) INPPL1INPP5AAKT1INPP5BSRC
SCHEMBL28505708 0.85 INPPL1 (0.41) INPPL1INPP5AAKT1INPP5BSRC
SCHEMBL554860 0.80 FDPS (0.39) INPPL1INPP5AAKT1INPP5BFDPS
SCHEMBL14956572 0.79 FDPS (0.38) INPPL1INPP5AAKT1INPP5BFDPS
SCHEMBL4181314 0.78 INPPL1 (0.60) INPPL1INPP5AAKT1INPP5BSRC
SCHEMBL6273605 0.77 CA1 (0.36) CA1CA2CA9
SCHEMBL28983527 0.75 INPPL1 (0.41) INPPL1INPP5AAKT1INPP5BSRC
SCHEMBL10942731 0.75 INPPL1 (0.41) INPPL1INPP5AAKT1INPP5BSRC
SCHEMBL11334192 0.74 CA1 (0.35) CA1CA2CA9
SCHEMBL9538185 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963536-A2 POLYMERASES FOR NUCLEOTIDE ANALOGUE INCORPORATION Pacific Biosciences of California, Inc. (US) 2008-09-03 EP claimed
US-20070196846-A1 Polymerases for nucleotide analogue incorporation PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2007-08-23 US claimed
WO-2007076057-A2 POLYMERASES FOR NUCLEOTIDE ANALOGUE INCORPORATION PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2007-07-05 WO claimed
CN-86104458-A With affinity chromatography purifying haemachrome and improvement haemachrome 1987-07-01 CN claimed
US-20240215624-A1 PROCESSED DAIRY-TYPE FOOD PRODUCTS BK GIULINI GMBH (DE) 2024-07-04 US disclosed
EP-4262414-A1 PROCESSED DAIRY-TYPE FOOD PRODUCTS BK Giulini GmbH (DE) 2023-10-25 EP disclosed
US-20230176481-A1 FILM-FORMING COMPOSITION NISSAN CHEMICAL CORPORATION (JP) 2023-06-08 US disclosed
WO-2022129525-A1 PROCESSED DAIRY-TYPE FOOD PRODUCTS BK GIULINI GMBH (DE) 2022-06-23 WO disclosed
EP-3056575-A1 POLYMERASES FOR NUCLEOTIDE ANALOGUE INCORPORATION Pacific Biosciences Of California, Inc. (US) 2016-08-17 EP disclosed
US-9133231-B2 Compounds for treating bacterial infections YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2015-09-15 US disclosed
US-20130203694-A1 COMPOUNDS FOR TREATING BACTERIAL INFECTIONS YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2013-08-08 US disclosed
EP-2601205-A2 GUANINE NUCLEOTIDE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (IL) 2013-06-12 EP disclosed
US-20030155123-A1 Method of treating reservoir zone of hydrocarbon producing well to inhibit water production problerms STATOIL ASA (NO) 2003-08-21 US disclosed
EP-1257727-A1 METHOD OF TREATING RESERVOIR ZONE OF HYDROCARBON PRODUCING WELL TO INHIBIT WATER PRODUCTION PROBLEMS Statoil ASA (NO) 2002-11-20 EP disclosed
WO-2001059255-A1 METHOD OF TREATING RESERVOIR ZONE OF HYDROCARBON PRODUCING WELL TO INHIBIT WATER PRODUCTION PROBLEMS STATOIL ASA (NO) 2001-08-16 WO disclosed
CN-1173220-A Methods and packaging designs for cryopreservation and storage of cultured tissue equivalents ORGANOGENESIS INC (US) 1998-02-11 CN disclosed
US-5656541-A HEATING A RARE EARTH OXIDE AND PHOSPHORIC ACID TO FORM A MIXED OXIDE COMPOUND, FIRING TO EVOLVE PHOSPHORUS OXIDE TO DEPOSIT A GLASSY COATING OF SPECIFIED THICKNESS ON A SILICON WAFER TECHNEGLAS, INC. (US) 1997-08-12 US disclosed
US-5350461-A Semiconductors TECHNEGLAS, INC. (US) 1994-09-27 US disclosed
EP-0022757-B1 METHOD FOR DETERMINING CREATINE KINASE IN SAMPLES CONTAINING ATP LKB-Produkter AB (SE) 1984-09-19 EP disclosed
EP-0022757-A1 Method for determining creatine kinase in samples containing ATP LKB-Produkter AB (SE) 1981-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070196846-A1 Polymerases for nucleotide analogue incorporation POLN, POLB, POLM INPPL1 445/4885INPP5A 459/4885AKT1 2496/4885
US-20130203694-A1 COMPOUNDS FOR TREATING BACTERIAL INFECTIONS REL, RELA, RRP1B INPPL1 2573/4885INPP5A 1906/4885AKT1 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.